Clinical Report: PRP Treatment in the Clinic

Overview

Platelet-rich plasma (PRP) has shown promise in enhancing nerve growth and improving gland function in patients with dry eye disease (DED) and neuropathic pain. A novel formulation of PRP eye drops demonstrated significant improvements in symptoms and signs compared to traditional treatments.

Background

Expand on the limitations of current DED treatments to highlight the need for PRP.

Data Highlights

Recent studies have indicated that PRP eye drops significantly improve Ocular Surface Disease Index (OSDI) scores and superficial corneal staining in DED patients compared to autologous serum (AS) drops.

Key Findings

• PRP contains a 20-fold higher concentration of nerve growth factors compared to AS.
• PRP eye drops can alleviate neuropathic pain associated with DED.
• Innovative storage methods for PRP maintain its efficacy while preventing clotting and bacterial growth.
• Clinical trials have shown PRP to outperform conventional artificial tears in symptom relief and ocular surface healing.
• Corneal confocal microscopy (CCM) studies confirm that DED can cause significant corneal nerve damage, correlating with pain levels.

Clinical Implications

Clinicians should consider PRP as a viable treatment option for patients with moderate to severe DED, particularly those with neuropathic pain. The development of effective PRP formulations can enhance patient outcomes and provide an alternative for those unresponsive to standard therapies.

Conclusion

Reiterate the importance of further research and potential future applications of PRP in ophthalmology.

References

1. A Comprehensive Review of Platelet-Rich Plasma Therapy for Erectile Dysfunction and Peyronie’s Disease, Springer, 2024 -- Platelet-Rich Plasma Therapy
2. Intra-Articular Applications of Platelet-Rich Plasma: A Comprehensive Review of Preclinical and Clinical Evidence for Joint Degeneration Management, Knee Surgery, Sports Traumatology, Arthroscopy, 2013 -- PRP Applications
3. Evaluation of Short-Term Outcomes from Single-Dose Intra-Articular Peptide Compared to Hyaluronic Acid and Platelet-Rich Plasma Injections in Knee Osteoarthritis: A Randomized Trial, Clinical Rheumatology, 2020 -- Intra-Articular Injections
4. TFOS DEWS III: Management and Therapy, ScienceDirect, 2025 -- Management of Dry Eye Disease
5. Blood-Derived Eye Drops for the Treatment of Corneal Neuropathic Pain, PMC -- Eye Drops for Neuropathic Pain
6. Retinal Physician — Panretinal Photocoagulation: Practical Guidelines and Considerations
7. TFOS DEWS III: Management and Therapy
8. Recent trial and synthesis data on PRP in DED
9. Blood-Derived Eye Drops for the Treatment of Corneal Neuropathic Pain - PMC